⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Vanqua Bio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Vanqua Bio
↗Chicago, USA
Vanqua Bio is a privately held, clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases. The company leverages a proprietary technology platform that utilizes human genetics and patient-derived induced pluripotent stem cell (iPSC) neuronal models to identify and validate novel disease pathways, specifically focusing on lysosomal dysfunction and the innate immune system.
Vanqua Bio's lead therapeutic focus is on Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB), particularly targeting the GBA1 gene and the glucocerebrosidase (GCase) enzyme. The company aims to develop small-molecule allosteric activators of GCase to restore lysosomal function and reduce the accumulation of toxic proteins like alpha-synuclein.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Neurodegenerative diseases
SIZE & FINANCIALS
Employees:1-50
Revenue:$10M-$25M
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$130M
Investors:Omega Funds, OrbiMed, Surveyor Capital (Citadel), Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly and Company, Logos Capital, Osage University Partners
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1 (VQ-101)
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Biogen (Licensed exclusive worldwide rights to Vanqua's preclinical oral C5aR1 antagonist in Oct 2025)
COMPETITION
Position:Emerging
Competitors:Alector, Juvenescence, Annexon
LEADERSHIP
Key Executives:
Jim Sullivan - CEO
Maurizio Facheris - Chief Medical Officer
Omer Siddiqui - Chief Development Officer
Scientific Founders:Dimitri Krainc, Jim Sullivan
Board Members:Mona Ashiya, Uya Chuluunbaatar, Bernard Davitian, Jonathan Silverstein, Hunter Smith, Rand Sutherland
LINKS
Website:vanquabio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Vanqua Bio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.